These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 16432175)

  • 1. Benzodiazepinedione inhibitors of the Hdm2:p53 complex suppress human tumor cell proliferation in vitro and sensitize tumors to doxorubicin in vivo.
    Koblish HK; Zhao S; Franks CF; Donatelli RR; Tominovich RM; LaFrance LV; Leonard KA; Gushue JM; Parks DJ; Calvo RR; Milkiewicz KL; Marugán JJ; Raboisson P; Cummings MD; Grasberger BL; Johnson DL; Lu T; Molloy CJ; Maroney AC
    Mol Cancer Ther; 2006 Jan; 5(1):160-9. PubMed ID: 16432175
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of Wild-Type p53-Expressing AML by the Novel Small Molecule HDM2 Inhibitor CGM097.
    Weisberg E; Halilovic E; Cooke VG; Nonami A; Ren T; Sanda T; Simkin I; Yuan J; Antonakos B; Barys L; Ito M; Stone R; Galinsky I; Cowens K; Nelson E; Sattler M; Jeay S; Wuerthner JU; McDonough SM; Wiesmann M; Griffin JD
    Mol Cancer Ther; 2015 Oct; 14(10):2249-59. PubMed ID: 26206331
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Implementation of a 220,000-compound HCS campaign to identify disruptors of the interaction between p53 and hDM2 and characterization of the confirmed hits.
    Dudgeon DD; Shinde S; Hua Y; Shun TY; Lazo JS; Strock CJ; Giuliano KA; Taylor DL; Johnston PA; Johnston PA
    J Biomol Screen; 2010 Aug; 15(7):766-82. PubMed ID: 20639499
    [TBL] [Abstract][Full Text] [Related]  

  • 4. USP7 inhibitor P22077 inhibits neuroblastoma growth via inducing p53-mediated apoptosis.
    Fan YH; Cheng J; Vasudevan SA; Dou J; Zhang H; Patel RH; Ma IT; Rojas Y; Zhao Y; Yu Y; Zhang H; Shohet JM; Nuchtern JG; Kim ES; Yang J
    Cell Death Dis; 2013 Oct; 4(10):e867. PubMed ID: 24136231
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alterations in gene expression and sensitivity to genotoxic stress following HdmX or Hdm2 knockdown in human tumor cells harboring wild-type p53.
    Heminger K; Markey M; Mpagi M; Berberich SJ
    Aging (Albany NY); 2009 Jan; 1(1):89-108. PubMed ID: 19946469
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Levels of HdmX expression dictate the sensitivity of normal and transformed cells to Nutlin-3.
    Patton JT; Mayo LD; Singhi AD; Gudkov AV; Stark GR; Jackson MW
    Cancer Res; 2006 Mar; 66(6):3169-76. PubMed ID: 16540668
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel 1,4-benzodiazepine-2,5-diones as Hdm2 antagonists with improved cellular activity.
    Leonard K; Marugan JJ; Raboisson P; Calvo R; Gushue JM; Koblish HK; Lattanze J; Zhao S; Cummings MD; Player MR; Maroney AC; Lu T
    Bioorg Med Chem Lett; 2006 Jul; 16(13):3463-8. PubMed ID: 16647257
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HDM2 impairs Noxa transcription and affects apoptotic cell death in a p53/p73-dependent manner in neuroblastoma.
    Shi Y; Takenobu H; Kurata K; Yamaguchi Y; Yanagisawa R; Ohira M; Koike K; Nakagawara A; Jiang LL; Kamijo T
    Eur J Cancer; 2010 Aug; 46(12):2324-34. PubMed ID: 20591651
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HDM2 regulation by AURKA promotes cell survival in gastric cancer.
    Sehdev V; Katsha A; Arras J; Peng D; Soutto M; Ecsedy J; Zaika A; Belkhiri A; El-Rifai W
    Clin Cancer Res; 2014 Jan; 20(1):76-86. PubMed ID: 24240108
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1.
    Ambrosini G; Sambol EB; Carvajal D; Vassilev LT; Singer S; Schwartz GK
    Oncogene; 2007 May; 26(24):3473-81. PubMed ID: 17146434
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antisense anti-MDM2 oligonucleotides as a novel therapeutic approach to human breast cancer: in vitro and in vivo activities and mechanisms.
    Wang H; Nan L; Yu D; Agrawal S; Zhang R
    Clin Cancer Res; 2001 Nov; 7(11):3613-24. PubMed ID: 11705884
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SCH529074, a small molecule activator of mutant p53, which binds p53 DNA binding domain (DBD), restores growth-suppressive function to mutant p53 and interrupts HDM2-mediated ubiquitination of wild type p53.
    Demma M; Maxwell E; Ramos R; Liang L; Li C; Hesk D; Rossman R; Mallams A; Doll R; Liu M; Seidel-Dugan C; Bishop WR; Dasmahapatra B
    J Biol Chem; 2010 Apr; 285(14):10198-212. PubMed ID: 20124408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ribosomal L1 domain-containing protein 1 coordinates with HDM2 to negatively regulate p53 in human colorectal Cancer cells.
    Ding L; Zhang Z; Zhao C; Chen L; Chen Z; Zhang J; Liu Y; Nie Y; He Y; Liao K; Zhang X
    J Exp Clin Cancer Res; 2021 Aug; 40(1):245. PubMed ID: 34362424
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A small synthetic peptide, which inhibits the p53-hdm2 interaction, stimulates the p53 pathway in tumour cell lines.
    Chène P; Fuchs J; Bohn J; García-Echeverría C; Furet P; Fabbro D
    J Mol Biol; 2000 May; 299(1):245-53. PubMed ID: 10860736
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery and cocrystal structure of benzodiazepinedione HDM2 antagonists that activate p53 in cells.
    Grasberger BL; Lu T; Schubert C; Parks DJ; Carver TE; Koblish HK; Cummings MD; LaFrance LV; Milkiewicz KL; Calvo RR; Maguire D; Lattanze J; Franks CF; Zhao S; Ramachandren K; Bylebyl GR; Zhang M; Manthey CL; Petrella EC; Pantoliano MW; Deckman IC; Spurlino JC; Maroney AC; Tomczuk BE; Molloy CJ; Bone RF
    J Med Chem; 2005 Feb; 48(4):909-12. PubMed ID: 15715460
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The initial evaluation of non-peptidic small-molecule HDM2 inhibitors based on p53-HDM2 complex structure.
    Zhao J; Wang M; Chen J; Luo A; Wang X; Wu M; Yin D; Liu Z
    Cancer Lett; 2002 Sep; 183(1):69-77. PubMed ID: 12049816
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RITA enhances chemosensivity of pre-B ALL cells to doxorubicin by inducing p53-dependent apoptosis.
    Kazemi A; Safa M; Shahbazi A
    Hematology; 2011 Jul; 16(4):225-31. PubMed ID: 21756539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted Brain Tumor Therapy by Inhibiting the MDM2 Oncogene: In Vitro and In Vivo Antitumor Activity and Mechanism of Action.
    Punganuru SR; Artula V; Zhao W; Rajaei M; Deokar H; Zhang R; Buolamwini JK; Srivenugopal KS; Wang W
    Cells; 2020 Jul; 9(7):. PubMed ID: 32630235
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Requirement for HDM2 activity in the rapid degradation of p53 in neuroblastoma.
    Isaacs JS; Saito S; Neckers LM
    J Biol Chem; 2001 May; 276(21):18497-506. PubMed ID: 11279110
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibiting MDM2-p53 Interaction Suppresses Tumor Growth in Patient-Derived Non-Small Cell Lung Cancer Xenograft Models.
    Hai J; Sakashita S; Allo G; Ludkovski O; Ng C; Shepherd FA; Tsao MS
    J Thorac Oncol; 2015 Aug; 10(8):1172-80. PubMed ID: 26200271
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.